Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Seocalcitol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR known ✓ | P11473 | 13/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.70 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.70 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.70 |
| ▸ | PGR | P06401 | 2/20 | 0.70 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.70 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.70 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.70 |
| ▸ | HTR1A | P08908 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.64 |
| ▸ | GC | P02774 | 1/20 | 0.64 |
| ▸ | RXRA | P19793 | 1/20 | 0.64 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.64 |
| ▸ | CNR1 | P21554 | 1/20 | 0.64 |
| ▸ | HTR2C | P28335 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Seocalcitol SCHEMBL12028975 | 1.00 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR | |
| Seocalcitol SCHEMBL5003622 | 1.00 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR | |
| Seocalcitol SCHEMBL29836063 | 1.00 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR | |
| Seocalcitol SCHEMBL14146667 | 1.00 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR | |
| Seocalcitol SCHEMBL5003623 | 1.00 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR | |
| Seocalcitol SCHEMBL24066895 | 1.00 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR | |
| Seocalcitol SCHEMBL3791 | 1.00 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR | |
| Seocalcitol SCHEMBL8219733 | 1.00 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR | |
| Seocalcitol SCHEMBL3790 | 1.00 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR | |
| Seocalcitol SCHEMBL14112510 | 1.00 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | CAMP4 THERAPEUTICS CORPORATION | 2022-04-07 | — | — | US | disclosed |
| EP-2681311-B1 | ACTIVE VITAMIN D OR ANALOGS THEREOF FOR USE IN IN VITRO FERTILIZATION | RIGSHOSPITALET COPENHAGEN UNIV HOSPITAL (DK) | 2018-03-28 | — | — | EP | disclosed |
| US-20140100419-A1 | ACTIVE VITAMIN D OR ANALOGS THEREOF FOR USE IN IN VIVO OR IN VITRO FERTILIZATION | RIGSHOSPITALET COPENHAGEN UNIVERSITY HOSPITAL (DK) | 2014-04-10 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| WO-2011017809-A1 | AUTOPHAGY INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS FOR THE USE THEREOF IN THE TREATMENT OF CANCER | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-02-17 | — | — | WO | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | PNPLA2, LIPC, PNLIP | VDR 1345/4885ADORA3 1503/4885SLC6A2 2002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.